https://lipidor2022.mkdev.nu/mfn-news/ 2023-10-03T11:11:26+00:00 https://lipidor2022.mkdev.nu/mfn-news/emollivet-reaches-milestone-of-over-1000-products-sold-and-prepares-for-scaled-up-production/ 2022-10-07T06:15:00+00:00 https://lipidor2022.mkdev.nu/mfn-news/emollivet-nar-milstolpe-med-over-1000-salda-produkter-och-forbereder-nu-for-uppskalad-produktion/ 2022-10-07T06:15:00+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-announces-results-from-the-companys-clinical-phase-iii-study-of-akp02-for-psoriasis/ 2022-10-28T10:13:00+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-meddelar-resultat-fran-bolagets-kliniska-fas-iii-studie-av-akp02-mot-psoriasis/ 2022-10-28T10:13:00+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-provides-update-following-outcome-of-phase-iii-study-of-psoriasis-candidate-akp02/ 2022-11-15T07:00:00+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-lamnar-uppdatering-efter-utfall-av-fas-iii-studien-med-psoriasiskandidaten-akp02/ 2022-11-15T07:00:00+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-ab-publ-publishes-interim-report-for-third-quarter-2022/ 2022-11-23T07:30:00+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-ab-publ-offentliggor-delarsrapport-for-tredje-kvartalet-2022/ 2022-11-23T07:30:00+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-presents-nomination-committee-3/ 2022-12-08T13:30:00+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-presenterar-valberedningen-3/ 2022-12-08T13:30:00+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-secures-bridge-financing-of-at-least-sek-5-million-through-loans-and-subsidiary-share-sales-and-takes-cost-saving-measures-including-staff-layoffs/ 2022-12-14T12:34:00+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-sakrar-bryggfinansiering-om-minst-5-msek-genom-lan-och-forsaljning-av-dotterbolagsaktier-samt-vidtar-atgarder-for-kostnadsbesparing-inklusive-uppsagningar-av-personal/ 2022-12-14T12:34:00+00:00 https://lipidor2022.mkdev.nu/mfn-news/the-board-of-lipidor-resolves-to-summon-an-extraordinary-general-meeting-for-approval-of-the-sale-of-subsidiary-shares-to-major-owners/ 2022-12-23T07:30:00+00:00 https://lipidor2022.mkdev.nu/mfn-news/styrelsen-i-lipidor-beslutar-om-att-kalla-till-extra-bolagsstamma-for-godkannande-av-forsaljning-av-dotterbolagsaktier-till-storre-agare/ 2022-12-23T07:30:00+00:00 https://lipidor2022.mkdev.nu/mfn-news/notice-of-extraordinary-general-meeting-in-lipidor-ab-publ-2/ 2022-12-23T07:45:00+00:00 https://lipidor2022.mkdev.nu/mfn-news/kallelse-till-extra-bolagsstamma-i-lipidor-ab-publ-3/ 2022-12-23T07:45:00+00:00 https://lipidor2022.mkdev.nu/mfn-news/bulletin-from-the-extraordinary-general-meeting-of-lipidor-ab-publ-2/ 2023-01-17T13:55:00+00:00 https://lipidor2022.mkdev.nu/mfn-news/kommunike-fran-extra-bolagsstamma-i-lipidor-ab-publ-2/ 2023-01-17T13:55:00+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-ab-publ-publishes-year-end-report-for-2022/ 2023-02-22T07:30:00+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-ab-publ-offentliggor-bokslutskommunike-for-2022/ 2023-02-22T07:30:00+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-ab-publ-publishes-annual-report-for-2022/ 2023-04-26T14:00:00+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-ab-publ-offentliggor-arsredovisning-for-2022/ 2023-04-26T14:00:00+00:00 https://lipidor2022.mkdev.nu/mfn-news/notice-of-annual-general-meeting-in-lipidor-ab-publ-3/ 2023-05-09T06:00:00+00:00 https://lipidor2022.mkdev.nu/mfn-news/kallelse-till-arsstamma-i-lipidor-ab-publ-4/ 2023-05-09T06:00:00+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-ab-publ-publishes-interim-report-for-q1-2023/ 2023-05-11T06:30:00+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-ab-publ-offentliggor-delarsrapport-for-forsta-kvartalet-2023/ 2023-05-11T06:30:00+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-updates-on-development-of-akp02/ 2023-05-26T11:15:00+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-uppdaterar-om-utvecklingen-for-akp02/ 2023-05-26T11:15:00+00:00 https://lipidor2022.mkdev.nu/mfn-news/bulletin-from-the-annual-general-meeting-of-lipidor-ab-publ-3/ 2023-06-08T13:45:00+00:00 https://lipidor2022.mkdev.nu/mfn-news/kommunike-fran-arsstamma-i-lipidor-ab-publ-3/ 2023-06-08T13:45:00+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-signs-agreement-for-clinical-phase-iii-study/ 2023-10-03T11:11:05+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-tecknar-avtal-for-klinisk-fas-iii-studie/ 2023-10-03T11:11:05+00:00 https://lipidor2022.mkdev.nu/mfn-news/rattelse-lipidor-ab-publ-offentliggor-delarsrapport-for-andra-kvartalet-2023/ 2023-10-03T11:11:05+00:00 https://lipidor2022.mkdev.nu/mfn-news/correction-lipidor-ab-publ-publishes-interim-report-for-q2-2023/ 2023-10-03T11:11:05+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-ab-publ-publishes-interim-report-for-q2-2023/ 2023-10-03T11:11:05+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-ab-publ-offentliggor-delarsrapport-for-andra-kvartalet-2023/ 2023-10-03T11:11:05+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-announcement-of-short-term-funding/ 2023-10-03T11:11:06+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-besked-om-kortsiktig-finansiering/ 2023-10-03T11:11:06+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-lakemedelsverket-bekraftar-den-kliniska-planen-for-ny-version-av-akp02/ 2023-10-03T11:11:06+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-swedish-medical-products-agency-confirms-clinical-plan-for-new-version-of-akp02/ 2023-10-03T11:11:06+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-uppdaterar-om-sin-kliniska-fas-iii-studie-med-psoriasiskandidaten-akp02/ 2023-10-03T11:11:11+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-updates-on-phase-iii-clinical-study-of-psoriasis-candidate-akp02/ 2023-10-03T11:11:11+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-utser-charlotta-ekman-som-ny-chief-financial-officer/ 2023-10-03T11:11:11+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-appoints-new-cfo-charlotta-ekman/ 2023-10-03T11:11:11+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-ab-publ-publishes-interim-report-for-second-quarter-2022/ 2023-10-03T11:11:11+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-ab-publ-offentliggor-delarsrapport-for-andra-kvartalet-2022/ 2023-10-03T11:11:11+00:00 https://lipidor2022.mkdev.nu/mfn-news/samtliga-patienter-i-lipidors-fas-iii-studie-med-psoriasiskandidaten-akp02-ar-fardigbehandlade/ 2023-10-03T11:11:11+00:00 https://lipidor2022.mkdev.nu/mfn-news/all-patients-in-lipidors-phase-iii-study-with-psoriasis-candidate-akp02-have-completed-treatment/ 2023-10-03T11:11:12+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidors-phase-iii-study-of-akp02-for-treatment-of-psoriasis-now-fully-recruited-results-expected-q3-2022/ 2023-10-03T11:11:12+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidors-fas-iii-studie-med-akp02-for-behandling-av-psoriasis-ar-fullrekryterad-resultat-vantas-under-q3-2022/ 2023-10-03T11:11:12+00:00 https://lipidor2022.mkdev.nu/mfn-news/bulletin-from-the-annual-general-meeting-of-lipidor-ab-publ/ 2023-10-03T11:11:12+00:00 https://lipidor2022.mkdev.nu/mfn-news/kommunike-fran-arsstamma-i-lipidor-ab-publ/ 2023-10-03T11:11:12+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-updates-on-phase-iii-study-of-akp02-in-treatment-of-psoriasis-half-of-patients-now-recruited/ 2023-10-03T11:11:12+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-uppdaterar-om-fas-iii-studien-med-akp02-for-behandling-av-psoriasis-halften-av-patienterna-rekryterade/ 2023-10-03T11:11:12+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-ab-publ-publishes-interim-report-for-first-quarter-2022/ 2023-10-03T11:11:12+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-ab-publ-offentliggor-delarsrapport-for-forsta-kvartalet-2022/ 2023-10-03T11:11:13+00:00 https://lipidor2022.mkdev.nu/mfn-news/kallelse-till-arsstamma-i-lipidor-ab-publ/ 2023-10-03T11:11:13+00:00 https://lipidor2022.mkdev.nu/mfn-news/notice-of-annual-general-meeting-in-lipidor-ab-publ/ 2023-10-03T11:11:13+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-ab-publ-offentliggor-arsredovisning-for-2021/ 2023-10-03T11:11:13+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-ab-publ-publishes-annual-report-for-2021/ 2023-10-03T11:11:13+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-starker-sitt-operativa-team-och-rekryterar-supply-chain-operations-manager/ 2023-10-03T11:11:13+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-strengthens-its-operational-team-and-recruits-supply-chain-operations-manager/ 2023-10-03T11:11:13+00:00 https://lipidor2022.mkdev.nu/mfn-news/djurhalsobolaget-emollivet-tar-in-kapital-och-forstarker-teamet/ 2023-10-03T11:11:13+00:00 https://lipidor2022.mkdev.nu/mfn-news/emollivet-lanserar-spray-for-hastar-med-mugg-rasp-och-skorv/ 2023-10-03T11:11:13+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-ab-publ-offentliggor-bokslutskommunike-for-2021/ 2023-10-03T11:11:13+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-ab-publ-publishes-year-end-report-for-2021/ 2023-10-03T11:11:14+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-announces-enrolment-of-first-patients-in-a-phase-iii-study-on-akp02-for-treatment-of-psoriasis/ 2023-10-03T11:11:14+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-meddelar-att-de-forsta-patienterna-har-rekryterats-till-fas-iii-studien-med-akp02-for-behandling-av-plackpsoriasis/ 2023-10-03T11:11:14+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-expands-clinical-program-announces-investment-in-new-drug-development-project-against-acne-vulgaris/ 2023-10-03T11:11:14+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-utokar-det-kliniska-programmet-offentliggor-satsning-pa-ett-nytt-lakemedelsutvecklingsprojekt-mot-akne/ 2023-10-03T11:11:14+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-presenterar-valberedningen/ 2023-10-03T11:11:14+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-presents-nomination-committee/ 2023-10-03T11:11:14+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-publishes-interim-report-for-period-1-january-30-september-and-q3-2021/ 2023-10-03T11:11:14+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-publicerar-delarsrapport-for-perioden-1-januari-30-september-och-det-tredje-kvartalet-2021/ 2023-10-03T11:11:15+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-lamnar-in-en-ny-patentansokan-och-utokar-samarbetet-med-cannassure-om-medicinska-cannabisprodukter-baserade-pa-lipidors-akvano-teknologi/ 2023-10-03T11:11:15+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-submits-new-patent-application-and-expands-collaboration-with-cannassure-using-lipidors-akvano-technology-for-medicinal-cannabis-products/ 2023-10-03T11:11:15+00:00 https://lipidor2022.mkdev.nu/mfn-news/warrant-holders-exercise-all-warrants-in-lipidors-incentive-program-2018-2021/ 2023-10-03T11:11:15+00:00 https://lipidor2022.mkdev.nu/mfn-news/optionsinnehavare-i-lipidor-utnyttjar-samtliga-teckningsoptioner-i-incitamentsprogrammet-2018-2021/ 2023-10-03T11:11:15+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-announces-approval-to-start-phase-iii-clinical-study-of-drug-candidate-akp02-for-treatment-of-psoriasis/ 2023-10-03T11:11:15+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-meddelar-godkannande-for-studiestart-av-klinisk-fas-iii-studie-av-psoriasiskandidaten-akp02/ 2023-10-03T11:11:15+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-publishes-interim-report-for-h1-2021/ 2023-10-03T11:11:15+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-publicerar-delarsrapport-for-h1-2021/ 2023-10-03T11:11:15+00:00 https://lipidor2022.mkdev.nu/mfn-news/sommarbrev-fran-lipidor/ 2023-10-03T11:11:16+00:00 https://lipidor2022.mkdev.nu/mfn-news/summer-letter-from-lipidor/ 2023-10-03T11:11:16+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-ab-licence-agreement-grants-menarini-group-company-relife-srl-exclusive-rights-to-register-promote-distribute-and-market-two-new-psoriasis-drug-candidates-for-potential-value-of-meur-70/ 2023-10-03T11:11:16+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-licensavtal-ger-menarini-group-bolaget-relife-srl-exklusiva-rattigheter-att-registrera-marknadsfora-distribuera-och-salja-tva-nya-psoriasis-lakemedelskandidater-med-potentiellt-varde-70-meur/ 2023-10-03T11:11:16+00:00 https://lipidor2022.mkdev.nu/mfn-news/bulletin-from-the-extraordinary-general-meeting-of-lipidor-ab-publ/ 2023-10-03T11:11:16+00:00 https://lipidor2022.mkdev.nu/mfn-news/kommunike-fran-extra-bolagsstamma-i-lipidor-ab-publ/ 2023-10-03T11:11:16+00:00 https://lipidor2022.mkdev.nu/mfn-news/bulletin-from-the-annual-general-meeting-of-lipidor-ab-publ-2/ 2023-10-03T11:11:16+00:00 https://lipidor2022.mkdev.nu/mfn-news/kommunike-fran-arsstamma-i-lipidor-ab-publ-2/ 2023-10-03T11:11:16+00:00 https://lipidor2022.mkdev.nu/mfn-news/notice-of-extraordinary-general-meeting-in-lipidor-ab-publ/ 2023-10-03T11:11:17+00:00 https://lipidor2022.mkdev.nu/mfn-news/kallelse-till-extra-bolagsstamma-i-lipidor-ab-publ/ 2023-10-03T11:11:17+00:00 https://lipidor2022.mkdev.nu/mfn-news/notice-of-annual-general-meeting-in-lipidor-ab-publ-2/ 2023-10-03T11:11:17+00:00 https://lipidor2022.mkdev.nu/mfn-news/kallelse-till-arsstamma-i-lipidor-ab-publ-2/ 2023-10-03T11:11:17+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-publishes-interim-report-for-q1-2021/ 2023-10-03T11:11:17+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-publicerar-delarsrapport-for-q1-2021/ 2023-10-03T11:11:17+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-publishes-annual-report-for-2020/ 2023-10-03T11:11:17+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-publicerar-arsredovisning-for-2020/ 2023-10-03T11:11:17+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidors-dotterforetag-emollivet-tar-nasta-steg-mot-lansering-och-finansieras-av-vinnova/ 2023-10-03T11:11:17+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidors-subsidiary-emollivet-takes-the-next-step-towards-launch-and-receives-funding-from-vinnova/ 2023-10-03T11:11:17+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-update-on-the-companys-phase-iii-clinical-trial-of-drug-candidate-akp02-for-treatment-of-psoriasis/ 2023-10-03T11:11:18+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-uppdatering-om-bolagets-kliniska-fas-iii-studie-med-lakemedelskandidaten-akp02-for-behandling-av-psoriasis/ 2023-10-03T11:11:18+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-presenterar-pa-erik-penser-banks-bolagsdag-den-11-mars/ 2023-10-03T11:11:18+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-ab-publ-publishes-year-end-report-for-2020/ 2023-10-03T11:11:18+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-ab-publ-offentliggor-bokslutskommunike-for-2020/ 2023-10-03T11:11:18+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-and-cannassure-enter-exclusive-licensing-agreement-regarding-topical-medical-cannabis-products-based-on-lipidors-akvano-technology/ 2023-10-03T11:11:18+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-och-cannassure-tecknar-exklusivt-licensavtal-avseende-topikala-medicinska-cannabisprodukter-baserade-pa-lipidors-akvano-teknologi/ 2023-10-03T11:11:18+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-tecknar-samarbetsavtal-med-kontraktstillverkare-for-att-kunna-erbjuda-licenstagare-mojlighet-till-gmp-produktion/ 2023-10-03T11:11:18+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-signs-cooperation-agreement-with-contract-manufacturer-to-offer-licensees-the-opportunity-for-gmp-production/ 2023-10-03T11:11:18+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-presents-nomination-committee-2/ 2023-10-03T11:11:18+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-presenterar-valberedningen-2/ 2023-10-03T11:11:19+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-publishes-interim-report-for-q3-2020/ 2023-10-03T11:11:19+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-publicerar-delarsrapport-for-q3-2020/ 2023-10-03T11:11:19+00:00 https://lipidor2022.mkdev.nu/mfn-news/rattelse-av-pressmeddelande-lipidor-tillfors-cirka-199-msek-till-foljd-av-utnyttjade-teckningsoptioner-av-serie-to1-2019/ 2023-10-03T11:11:19+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-tillfors-cirka-199-msek-till-foljd-av-utnyttjade-teckningsoptioner-av-serie-to1-2019/ 2023-10-03T11:11:19+00:00 https://lipidor2022.mkdev.nu/mfn-news/teckningskurs-faststalld-for-lipidors-teckningsoption-av-serie-to1-2019/ 2023-10-03T11:11:19+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-byter-certified-adviser-till-erik-penser-bank-ab/ 2023-10-03T11:11:19+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-strengthens-management-through-strategic-hire/ 2023-10-03T11:11:19+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-forstarker-ledningen-genom-en-strategisk-rekrytering/ 2023-10-03T11:11:19+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-announces-positive-outcome-of-feasibility-study-for-development-of-topical-medical-cannabis-products-based-on-the-companys-akvano-technology/ 2023-10-03T11:11:19+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-meddelar-positivt-utfall-av-genomforbarhetsstudien-for-utveckling-av-topikala-medicinska-cannabisprodukter-baserade-pa-bolagets-akvano-teknologi/ 2023-10-03T11:11:20+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-tillfors-350-msek-genom-riktad-nyemission-om-28-miljoner-aktier/ 2023-10-03T11:11:20+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-utreder-forutsattningarna-for-att-genomfora-en-riktad-nyemission/ 2023-10-03T11:11:20+00:00 https://lipidor2022.mkdev.nu/mfn-news/correction-lipidor-publishes-interim-report-for-h1-2020/ 2023-10-03T11:11:20+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-publishes-interim-report-for-h1-2020/ 2023-10-03T11:11:20+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-publicerar-delarsrapport-for-h1-2020/ 2023-10-03T11:11:20+00:00 https://lipidor2022.mkdev.nu/mfn-news/resolutions-from-lipidors-extraordinary-general-meeting/ 2023-10-03T11:11:20+00:00 https://lipidor2022.mkdev.nu/mfn-news/kommunike-fran-lipidors-extra-bolagsstamma/ 2023-10-03T11:11:20+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-tecknar-avtal-for-leverans-av-kliniskt-provningsmaterial-for-fas-iii-studien-med-akp02/ 2023-10-03T11:11:20+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-signs-agreement-with-cro-for-implementation-of-phase-iii-clinical-study-of-drug-candidate-akp-02-against-psoriasis/ 2023-10-03T11:11:20+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-tecknar-avtal-med-cro-for-genomforande-av-klinisk-fas-iii-studie-avseende-lakemedelskandidaten-akp-02-mot-psoriasis/ 2023-10-03T11:11:21+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-ab-publ-meddelar-att-dotterforetaget-emollivet-ab-rekryterat-stina-linge-som-vd/ 2023-10-03T11:11:21+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-ab-publ-announces-subsidiary-emollivet-abs-recruitment-of-stina-linge-as-ceo/ 2023-10-03T11:11:21+00:00 https://lipidor2022.mkdev.nu/mfn-news/notice-of-extraordinary-general-meeting-of-lipidor-ab-publ/ 2023-10-03T11:11:21+00:00 https://lipidor2022.mkdev.nu/mfn-news/kallelse-till-extra-bolagsstamma-i-lipidor-ab-publ-2/ 2023-10-03T11:11:21+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-ab-publ-formalizes-relationship-with-subsidiary-emollivet-ab-through-license-agreement-and-proposes-financing-of-subsidiary/ 2023-10-03T11:11:21+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-ab-publ-formaliserar-relationen-med-dotterforetaget-emollivet-ab-genom-licensavtal-och-foreslar-finansiering-av-dotterforetaget/ 2023-10-03T11:11:21+00:00 https://lipidor2022.mkdev.nu/mfn-news/kommunike-fran-arsstamma-i-lipidor-ab-den-11-juni-2020/ 2023-10-03T11:11:21+00:00 https://lipidor2022.mkdev.nu/mfn-news/resolutions-from-annual-general-meeting-11-june-2020/ 2023-10-03T11:11:21+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-publicerar-delarsrapport-for-q1-2020/ 2023-10-03T11:11:21+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-publishes-interim-report-for-q1-2020/ 2023-10-03T11:11:22+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-publicerar-arsredovisning-for-2019/ 2023-10-03T11:11:22+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-publishes-annual-report-for-2019/ 2023-10-03T11:11:22+00:00 https://lipidor2022.mkdev.nu/mfn-news/notice-of-annual-general-meeting-of-lipidor-ab-publ/ 2023-10-03T11:11:22+00:00 https://lipidor2022.mkdev.nu/mfn-news/kallelse-till-arsstamma-i-lipidor-ab-publ-3/ 2023-10-03T11:11:22+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-lamnar-uppdaterad-projektplan-initierar-fas-iii-studie-avseende-akp02-i-egen-regi/ 2023-10-03T11:11:22+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-presents-updated-project-plan-initiates-phase-iii-study-of-akp02-in-house/ 2023-10-03T11:11:22+00:00 https://lipidor2022.mkdev.nu/mfn-news/stor-efterfragan-pa-skin-disinfection-spray-fran-aurena-laboratories-i-samarbete-med-lipidor-snart-tillganglig-aven-hos-apotea/ 2023-10-03T11:11:22+00:00 https://lipidor2022.mkdev.nu/mfn-news/desinfektionsspray-fran-aurena-laboratories-baserad-pa-lipidors-akvano-teknologi-snart-tillganglig-pa-den-svenska-marknaden/ 2023-10-03T11:11:22+00:00 https://lipidor2022.mkdev.nu/mfn-news/new-disinfection-spray-from-lipidor-and-aurena-laboratories/ 2023-10-03T11:11:23+00:00 https://lipidor2022.mkdev.nu/mfn-news/ny-desinfektionsspray-fran-lipidor-och-aurena-laboratories/ 2023-10-03T11:11:23+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-ab-om-publicerar-bokslutskommuniken-for-2019/ 2023-10-03T11:11:23+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-ab-re-publishes-year-end-report-for-2019/ 2023-10-03T11:11:23+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-ab-publ-offentliggor-bokslutskommuniken-for-2019/ 2023-10-03T11:11:23+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-announces-positive-topline-results-of-akp01-phase-iii-clinical-study-using-calcipotriol-spray-against-psoriasis/ 2023-10-03T11:11:23+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-meddelar-idag-positiva-resultat-fran-bolagets-kliniska-fas-iii-studie-av-kalcipotriolspray-akp01-mot-psoriasis/ 2023-10-03T11:11:23+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-ab-publ-kk-stiftelsen-finansierar-samverkansprojekt-for-studier-av-hur-lakemedelsformuleringar-paverkar-hudbarriaren/ 2023-10-03T11:11:23+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-ab-publ-the-knowledge-foundation-funds-collaborative-project-to-study-the-effects-of-drug-formulations-on-the-skin-barrier/ 2023-10-03T11:11:23+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-ab-publ-updates-timetable-for-results-from-ongoing-phase-iii-study-marginal-shift-in-results-reporting/ 2023-10-03T11:11:23+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-ab-publ-uppdaterar-tidplan-for-resultat-fran-pagaende-fas-iii-studie-marginell-forskjutning-av-resultatrapportering/ 2023-10-03T11:11:24+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-nasdaq-first-north-lipi-och-cannassure-tasecsure-ingar-avtal-om-genomforbarhetsstudie-och-option-till-licens-for-utveckling-och-forsaljning-av-topikala-medicinska-cannabisprodukter/ 2023-10-03T11:11:24+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-nasdaq-first-north-lipi-and-cannassure-tasecsure-enter-a-feasibility-study-and-licence-option-agreement-for-development-and-sales-of-topical-medical-cannabis-products/ 2023-10-03T11:11:24+00:00 https://lipidor2022.mkdev.nu/mfn-news/correction-lipidor-ab-publ-publishes-interim-report-for-q3-2019/ 2023-10-03T11:11:24+00:00 https://lipidor2022.mkdev.nu/mfn-news/rattelse-lipidor-ab-publ-offentliggor-delarsrapport-for-q3-2019/ 2023-10-03T11:11:24+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-ab-publ-publishes-interim-report-for-q3-2019/ 2023-10-03T11:11:24+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-ab-publ-offentliggor-delarsrapport-for-q3-2019/ 2023-10-03T11:11:24+00:00 https://lipidor2022.mkdev.nu/mfn-news/sista-patienten-fardigbehandlad-i-lipidors-fas-iii-studie-med-kalcipotriol-akvano-spray-akp01-mot-psoriasis/ 2023-10-03T11:11:24+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-announces-last-patient-out-in-calcipotriol-akvano-spray-akp01-phase-iii-study-targeting-psoriasis/ 2023-10-03T11:11:24+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-has-been-approved-for-listing-on-the-nasdaq-first-north-growth-market-with-first-day-of-trading-on-september-27-2019/ 2023-10-03T11:11:25+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-har-godkants-for-listning-pa-nasdaq-first-north-growth-market-med-forsta-handelsdag-den-27-september-2019/ 2023-10-03T11:11:25+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidors-noteringsemission-tecknades-till-540/ 2023-10-03T11:11:25+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidors-new-share-issue-achieves-540-subscription/ 2023-10-03T11:11:25+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-announces-enrolment-of-last-patient-in-calcipotriol-akvano-spray-akp01-phase-iii-study-targeting-psoriasis/ 2023-10-03T11:11:25+00:00 https://lipidor2022.mkdev.nu/mfn-news/sista-patienten-inkluderad-i-lipidors-fas-iii-studie-med-kalcipotriol-akvano-spray-akp01-mot-psoriasis/ 2023-10-03T11:11:25+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-ab-publishes-information-memorandum-in-connection-with-a-new-issue-of-sek-25-2-million-prior-to-listing-on-nasdaq-first-north-growth-market-updated/ 2023-10-03T11:11:25+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-ab-offentliggor-informationsmemorandum-i-samband-med-nyemission-om-252-msek-infor-notering-pa-nasdaq-first-north-growth-market-uppdaterad/ 2023-10-03T11:11:25+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-ab-publishes-information-memorandum-in-connection-with-a-new-issue-of-sek-25-2-million-prior-to-listing-on-nasdaq-first-north-growth-market/ 2023-10-03T11:11:26+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-ab-offentliggor-informationsmemorandum-i-samband-med-nyemission-om-252-msek-infor-notering-pa-nasdaq-first-north-growth-market/ 2023-10-03T11:11:26+00:00 https://lipidor2022.mkdev.nu/mfn-news/decisions-from-annual-general-meeting-of-lipidor-ab-20-june-2019/ 2023-10-03T11:11:26+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-ab-successfully-completes-private-placement-of-20-msek/ 2023-10-03T11:11:26+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-first-patient-in-for-phase-iii-trial-of-calcipotriol-spray-a-new-high-comfort-high-control-anti-psoriasis-spray/ 2023-10-03T11:11:26+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-new-ceo-at-helm-as-company-gears-up-for-ipo/ 2023-10-03T11:11:26+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-gets-go-ahead-for-phase-iii-clinical-study-of-new-calcipotriol-spray-treatment-for-psoriasis/ 2023-10-03T11:11:26+00:00 https://lipidor2022.mkdev.nu/mfn-news/lipidor-ab-strengthens-its-board-and-aims-for-an-ipo-in-2019/ 2023-10-03T11:11:26+00:00